GlassScriptPhysician profile
Eugene Chaung
NPI 1659715571
$2,335.55
in general payments reported to CMS, 2019-2025
15 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $52.52 · 2021: $291 · 2022: $416 · 2023: $808 · 2024: $282 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $954.99 | 2021-2025 | Yeztugo, Descovy |
| Viiv Healthcare Company | $348.85 | 2022-2025 | Apretude |
| Phathom Pharmaceuticals, INC. | $130.94 | 2025 | Voquezna |
| Janssen Products, LP | $123.67 | 2022 | |
| Amgen INC. | $121.86 | 2023 | Evenity |
| Melinta Therapeutics, LLC | $121.41 | 2019-2021 | |
| Lilly USA, LLC | $117.97 | 2024 | Mounjaro |
| Janssen Biotech, INC. | $100.48 | 2019 | |
| Novo Nordisk INC | $86.64 | 2022 | |
| Theratechnologies INC. | $70.34 | 2023 | Trogarzo |
| Paratek Pharmaceuticals, INC. | $42.01 | 2021 | |
| Merck Sharp & Dohme LLC | $37.14 | 2020-2021 | |
| Shionogi INC | $36.90 | 2021 | |
| Allergan, INC. | $21.96 | 2020 | |
| Abbvie INC. | $20.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Chaung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.